U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07489534) titled 'Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction' on March 18.
Brief Summary: The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal dysfunction.
Study Start Date: Sept. 29, 2025
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: PD-1Ab21-BCMA CAR-T cell immunotherapy
Consolidation therapy with PD-1 antibody and BCMA-targeting CAR-T in multiple myeloma patients with renal impairment.
Rec...